Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM)

Victory Capital Management Inc. raised its holdings in Immunome, Inc. (NASDAQ:IMNM) by 48.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 730,785 shares of the company’s stock after purchasing an additional 237,497 shares during the period. Victory Capital Management Inc. owned 1.22% of Immunome worth $10,684,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Swiss National Bank acquired a new position in shares of Immunome during the 1st quarter worth approximately $1,762,000. Sei Investments Co. acquired a new stake in Immunome during the 1st quarter valued at $469,000. Vanguard Group Inc. increased its position in Immunome by 16.1% during the first quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock worth $49,847,000 after buying an additional 279,712 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Immunome by 602.1% in the first quarter. Acadian Asset Management LLC now owns 133,438 shares of the company’s stock worth $3,292,000 after acquiring an additional 114,433 shares during the last quarter. Finally, EntryPoint Capital LLC lifted its position in shares of Immunome by 21,864.0% in the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after acquiring an additional 5,466 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on IMNM shares. Stephens initiated coverage on Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company. Piper Sandler lowered their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Finally, Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome has a consensus rating of “Buy” and a consensus target price of $28.83.

Immunome Price Performance

IMNM opened at $9.33 on Thursday. The stock has a market capitalization of $582.35 million, a price-to-earnings ratio of -1.15 and a beta of 1.82. Immunome, Inc. has a 12 month low of $6.93 and a 12 month high of $30.96. The business has a 50-day moving average of $12.81 and a two-hundred day moving average of $13.67.

Insider Activity at Immunome

In related news, CFO Max Rosett sold 14,380 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the transaction, the chief financial officer now directly owns 47,476 shares of the company’s stock, valued at approximately $760,090.76. This trade represents a 23.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.60% of the stock is owned by insiders.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.